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BACKGROUND: Colorectal cancer is (CRC) one of the commonest cancers and its therapy is still based on few drugs. Currently,
no biological criteria are used to choose the most effective of the established drugs for treatment.
METHODS: A panel of 77 CRC cell lines was tested for sensitivity to 5-fluorouracil (5FU) using the SRB assay. The responses were
grouped into three categories and correlated with genetic changes in the cell lines.
RESULTS: The strongest and most clearcut correlation was between 5-fluorouracil response and replication error status (mismatch
repair deficiency). All the other significant correlations (loss of heterozygosity for DCC and mutations in TGFbIIR) are secondary to the
association with replication error status.
INTERPRETATION AND CONCLUSION: Our findings validate previous analyses based mainly on clinical data, and indicate that replication
error status could be a useful guide to 5-fluorouracil-based CRC therapy. Essentially, all previously described correlations with 5FU
response are secondary to the association with replication error status.
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Colorectal cancer (CRC) is one of the most commonly diagnosed
cancers in the western world (Rim et al, 2009), and the 5-year
relative survival rate is still only between 44 and 60% in the United
Kingdom and North America (Coleman et al, 2008). A wide range of
genetic changes due to mutations and loss of heterozygosity (LOH),
as well as epigenetic changes, are found in CRC, indicating the
considerable heterogeneity of the disease. Involved genes include
APC, KRAS, PIK3CA, BRAF, PTEN, SMAD4, MLH1, MSH2, TP53,
and CTNNB1 (Sanger Institute). KRAS activating mutations have
recently emerged as predictive biomarkers for treatment of CRC
with EGFR inhibiting agents in clinical trials (Linardou et al, 2008;
Riely and Ladanyi, 2008). Clinical data also suggest an association
between 5-fluorouracil (5FU) response and RER status (Ribic et al,
2003; Warusavitarne and Schnitzler, 2007; Muller et al,2 0 0 8 ) .T h e s e
studies extended findings by previous work on cell-based studies in
isogenic pairs of HCT116 cells (Meyers et al,2 0 0 1 ;A r n o l det al,
2003). So far, however, the KRAS association is the only predictive
marker that is being used to guide the treatment of CRC.
Advances in the chemotherapy treatment of CRC are limited by
the currently available selection of licensed drugs, most of which
(oxaliplatin, 5FU, irinotecan, and capecitabine) have been in use
for many years. The most recently introduced agents are
antibodies targeting EGFR (cetuximab and panitumumab) or
VEGF (bevacizumab). 5-Fluorouracil, which is also used in the
treatment of breast, stomach, and pancreatic cancer, remains the
cornerstone of CRC treatment, although widely used in combina-
tion with several other drugs (Kopetz, 2008). It is an antimetabolite
that, after conversion into its main active metabolites (FdI `MP,
FdUTP, and FUTP), induces, among other effects, RNA and DNA
damage through incorporation of its metabolites into nucleic
acids, and inhibition of thymidylate synthase (TS) and therefore
DNA synthesis (Longley et al, 2003). However, only 10–15% of
advanced CRC tumours treated with 5FU/leucovorin first-line
therapy respond (Longley et al, 2003; Chen et al, 2010), which
highlights the need to establish predictive biomarkers for 5FU drug
response.
We have accumulated in our laboratory a large collection of
CRC-derived cell lines on which we have information regarding
their genetic changes and variation in gene expression (see, e.g.,
Liu and Bodmer, 2006). This panel of cell lines provides a powerful
tool for detecting associations between drug responses and the
biological characteristics of the lines, which reflect the properties
of the tumours from which they were derived. The use of the cell
lines should, therefore, enable the discovery of new predictive
markers for better patient selection and more targeted therapy.
In this study we present a robust method for large-scale
screening of CRC cell lines directly from frozen stock and a simple
objective approach to the classification of the cell lines with respect
to their drug responses. Data from a screen of 5FU response in 77
cell lines were used for an analysis of correlations with genetic
changes. The results show, in agreement with published clinical
data, that the major genetic change affecting 5FU response is
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method of analysis.
MATERIALS AND METHODS
Cell lines
Details of the 77 cell lines used in this study are listed in
Supplementary Table 1. Many of the lines have been described
before (Liu and Bodmer, 2006). The cell lines were characterised
with respect to mismatch repair deficiency (replication error
status: RERþ for mismatch repair defective and RER  otherwise
(four microsatellite loci, BAT25, BAT26, D17S250, and D18S69,
were amplified and used to determine RER status; Efstathiou et al,
1999)), mutations in APC (mutation cluster region), KRAS (codons
12 and 13), BRAF (V600E), TP53, CDH1 (E-cadherin), CTNNB1
(b-catenin; exons 3, 4, 5, and 6), MLH1, MSH2, PIK3CA (exons 9
and 20), B2M (b-2-microglobulin, exons 1 and 2), TGFBR2
(TGFbIIR), CHK1, and SMAD4, LOH around the genes APC and
CDX1 (chromosome 5), SMAD4 and DCC (chromosome 18), and
promoter methylation of MLH1, MSH2, CDKN2A (p16), CDKN2B
(p15), and CDX1. Most cell lines have been HLA typed to identify
duplicate cell lines, and all cell lines were routinely tested negative
for mycoplasma.
Toxicity testing
Increased throughput was predominately achieved by plating cells
directly into 96-well plates from frozen stock, thus negating the
need for continuous culture of the cell lines. Optimal freezing and
thawing conditions were established and the time required, after
plating, for lines to begin their growth phase was determined and
defined as the lag time. Standard freezing conditions involved
suspending cells in 5% DMSO in FCS at a density of 4 10
6 cells
per ml and placing them on dry ice for 90min before transfer to
liquid nitrogen. For use from frozen stocks, cells were warmed
quickly to 371C and transferred immediately into prewarmed
medium, centrifuged, and re-suspended in fresh, DMSO-free
medium before use. Cell lines plated from thawed stocks were
shown to have the same growth curves and drug dose-response
curves as their cultured counterparts (data not shown). Lag times
and doubling time (d.b.t.) for all cell lines after plating from frozen
stock were established by plating 3000 cells per well and using the
SRB assay as described below. The results are reported in
Supplementary Table 1.
For toxicity testing, 3000 cells were plated in 100ml medium in
96-well plates and incubated for their lag time before drug
treatment with a further 100ml of drug-containing medium in
duplicate wells for each condition. Final concentrations of 5FU
ranged from 0.13 to 100mM (1:3 titration) and the final
concentration of DMSO in all wells was 0.067%. Cells were
incubated with drug for 3d.b.t. to accommodate for differences in
their growth rates, before they were fixed and stained following a
standard SRB protocol (Vichai and Kirtikara, 2006). In brief, after
spinning plates for 10min at 1500r.p.m., 50ml of ice-cold
trichloroacetic acid (2.6 M) was added and plates were incubated
at 41C for 60min. After washing the plates with 0.5  PBSA, cells
were stained with sulforhodamine B (0.04% in 1% acetic acid) for
30min, washed with acetic acid (1%), and bound dye was dissolved in
200mlT r i s( 1 0 m M,p H9 . 5 )b e f o r em e a s u r i n gt h eO Da t5 4 0 n mi n
a plate reader. T/Ccorr (%) (‘treated over control (corrected)’ with
a correction for the OD of the number of cells at the time
of treatment) is calculated as ((ODdrug, 3d.b.t. ODt0)/(ODDMSO control, 3d.b.t.
 ODt0)) 100, and GI50 values were calculated from the resulting
dose-response curves using model 210 (dose-response one site,
five-parameter logistic model, fit¼(Aþ((B A)/(1þx/C)^D))^E))),
A and B unlocked) in XLfit (IDBS, Surrey, UK). The experiment was
repeated two to four times for each cell line.
Matrigel assay
A total of 700 cells were plated in 80ml Matrigel (basement
membrane matrix, growth factor reduced, BD (Oxford, UK), no.
356231) in 96-well plates and treated with 0, 0.5, 5, and 50mM 5FU
in duplicate wells each (150ml per well added on top of Matrigel/
cells). The medium was exchanged for fresh drug-containing
medium on days 3, 6, 9, and 12 before colonies were counted under
a light microscope ( 10 objective) on day 14. Three fields of
vision (FOV) were counted per well, averaging counts per FOV
over both wells, and the experiment was repeated three times. Four
cell lines were chosen for their known different abilities to
differentiate in this matrix: LS174T and HT29 (intermediate
differentiation), and LS180 and SW1222 (well differentiated).
Statistical analysis
The 77 cell lines were divided into terciles with respect to their
sensitivity to 5FU: sensitive (n¼26), intermediate response
(n¼26), and resistant (n¼25). To correlate drug response with
categorical data (e.g., mutation status), we used w
2 association and
trend tests in 2 2 table and 3 2 tables for comparing categories
of drug response with two genetic categories (e.g., wild type and
mutant). For known duplicate cell lines, only one of each duplicate
was counted for association studies. When drug response group-
ings differed between duplicate lines, both duplicates were omitted
from the statistical analysis. Reported P-values were not corrected
for multiple testing.
RESULTS
5FU drug response
Overall, GI50 values ranged from 0.03 (HDC73) to 47.5mM (HCT15)
in the 77 cell lines, giving an approximately 1600-fold maximum
mM difference. Supplementary Table 2 lists the GI50 values for
all the cell lines, including duplicates, in alphabetical order and the
same data are shown in rank order in Figure 1. Examples of dose-
response curves for three cell lines with different levels of 5FU
sensitivity are given in Figure 2. The cell lines were
divided into three sensitivity groups, ranging from sensitive
(HDC73 to VACO10MS, 0.03–1.70mM) to intermediate (HDC54
to SKCO1, 1.76–6.14mM) to resistant (SNUC2B to HCT15,
6.18–47.5mM), as shown in Figure 1. There is good agreement
for the majority of pairs of duplicate cell lines. Thus, COLO201
and COLO206 (4.47 and 4.19mM), Gp2d and Gp5d (2.54 and
3.80mM), CACO2 and C2BBe1 (2.50 and 1.42mM), HDC54 and
HDC57 (1.76 and 1.03mM), and LS174T and LS180 (17.87
and 20.20mM) agree well with each other. There is a greater
difference between DLD1 and HCT15 (18.67 and 47.5mM), although
these two cell lines have the fourth highest and highest GI50 values,
respectively, and SW480 and SW620 (6.36 and 17.23mM), which
were established, respectively, from the primary tumour and a
metastasis. For all six pairs of these duplicate cell lines, both pairs
fall into the same response category. The differences are larger for
VACO4A and VACO4S (6.40 and 1.85mM), which were established
from adherent and supernatant subclones of the same cell line. The
generally good agreement between lines that have been separately
maintained in culture for several years suggests a good measure of
reproducibility in the drug response data that we have obtained,
and gives confidence to the validity in the categorisation of the cell
lines from sensitive to resistant.
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Because this is not a higher throughput assay, only four cell lines
(LS174T, LS180, SW1222, and HT29) were chosen for testing their
sensitivity to 5FU in a 3D colony-forming assay using Matrigel.
Two of these cell lines (SW1222 and LS180) readily form crypt-like
structures, indicating their capacity to differentiate in Matrigel,
whereas the other two (HT29 and LS174T) form crypt-like
structures to a much lesser extent (Yeung et al, 2010). All four
cell lines show a clear dose-response relationship (see Figure 3),
with nearly complete inhibition of colony growth at the highest
concentration of 5FU tested (50mM). There is no obvious
relationship between the ability to form crypt-like structures and
the 5FU response, suggesting that 5FU response is not related to
the differentiation capacity of the lines. For all four cell lines, the
concentration of 5FU that inhibits colony formation by 50% lies
between 0.5 and 5mM 5FU. This suggests a somewhat higher
sensitivity of the cell lines to 5FU in this clonogenicity assay than
in our conventional SRB toxicity test, for which GI50 values ranged
from 5.76 (SW1222) to 20.2mM (LS180).
Correlation with genetic data
The classification of the lines into three sensitivity categories for
5FU enables a simple test for association between 5FU response
and the genetic changes found in the cell lines. Visual inspection of
Figure 1 immediately suggests a strong association between RERþ
and 5FU resistance. This is confirmed by the statistical tests,
excluding duplicate cell lines, shown in Table 1. The only
significant associations among all the investigated parameters in
3 2 tables, testing for the association between the three categories
of 5FU response and pairs of somatic genetic differences in the cell
lines, are for RERþ vs RER  and for LOH around DCC,o n
chromosome 18. Mutations in TGFbIIR, which are nearly always
found in microsatellite unstable tumours because of a coding
mononucleotide repeat in the TGFbIIR gene (Markowitz et al,
1995; Samowitz et al, 2002), are on the margin of significance, with
P¼0.035. The LOH in SMAD4, also located on chromosome 18,
misses significance with P¼0.0759.
The LOH for chromosome 18 and mutations in TGFbIIR are well
known to be associated with RERþ vs RER  status (Woodford-
Richens et al, 2001), as also shown in our data in Table 2. This
clearly implies that all these other associations are secondary to
that with RERþ vs RER .
We also found a significant correlation between the d.b.t. of cell
lines and their sensitivity to 5FU in a t-test analysis, comparing the
average 5FU GI50 differences between the slow and fast (d.b.t. 448
and p48h, respectively) growing cell lines (P¼0.0005). Compar-
ing cell lines’ growth rate by RER status also gives a significant
result: the average d.b.t. for RERþ lines is 35.7h, whereas that for
RER  lines is longer (48.5h, P¼0.038, t-test) and this most
probably accounts for the d.b.t. association with 5FU response.
DISCUSSION
Our key observation is that 5FU resistance in our panel of 77 CRC
cell lines correlates strongly with mismatch repair deficiency, or
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adjuvant setting (Ribic et al, 2003; Warusavitarne and Schnitzler,
2007; Muller et al, 2008), and hence support the use of a panel of
cell lines for preclinical testing of associations of drug responses
with genetic changes in cancers. As a recent meta-analysis by
Des Guetz et al (2009) reported, the situation might be different in
metastatic cancer, in which they found an overall hazard ratio
(HR) of 0.83 for RERþ vs RER  patients treated with 5FU-based
chemotherapy. It has to be noted, however, that HR ratios varied
between 0.48 and 1.21 in the five studies selected by them.
When given no adjuvant chemotherapy, RERþ patients have an
overall better prognosis(de la Chapelle, 2003; Ribic et al, 2003), as
confirmed by a meta-analysis of 32 studies by Popat et al (2005).
This may be explained by immune response to the mutant proteins
that arise frequently in RERþ tumours because of frameshift
mutations (Bodmer et al, 1994; Saeterdal et al, 2001). This
suggestion is supported by the finding that RERþ tumours
are characterised by a higher rate of lymphocyte infiltration
(Buckowitz et al, 2005) that correlates with the total number of
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Table 1 Correlation of 5FU response with genetic data
5FU
P¼0.0022 1 (Sensitive) 2 (Intermediate) 3 (Resistant)
RER
+1 6 9
  22 13 11
5FU
P¼0.035 1 (Sensitive) 2 (Intermediate) and 3 (resistant)
TGFbIIR
mut 0 8
wt 3 2
5FU
P¼0.0016 1 (Sensitive) 2 (Intermediate) 3 (Resistant)
DCC
LOH 10 8 5
No LOH 0 3 8
Abbreviations: 5FU¼5-fluorouracil; LOH¼loss of heterozygosity; RER¼replication
error. P-values for the w
2 trend test are given for the 3 2 tables, and a P-value for
Fisher’s exact test for the 2 2 table. Although the given P-values are not corrected for
multiple testing, they remain significant for the RER+ vs RER  and LOH associations
even when multiplied by 23 (Bonferroni correction), which is the number of such
comparisons made. The only significant correlations are those shown in this table. Drug
response was tested for correlations with RER status, mutations in APC, kras, braf, TP53,
E-cahderin (CDH1), b-catenin (CTNNB1), MLH1, MSH2, PIK3CA, b-2-microglobulin (B2M),
TGFbIIR (TGFBR2), CHK1, SMAD4, LOH of APC, SMAD4, CDX1, DCC, and methylation of
MLH1, MSH2, p16 (CDKN2A), p15 (CDKN2B), and CDX1. Duplicate cell lines were
excluded from the analysis when they fell into different 5FU response groups and one of
the duplicate lines was included per pair when they fell into the same response category.
Table 2 Correlation between genetic variables and RER status
TGFbIIR
P¼0.003 wt mut
RER
+1 8
  50
DCC
Po0.0001 No LOH LOH
RER
+9 0
  22 3
Abbreviations: LOH¼loss of heterozygosity; RER¼replication error. The asso-
ciations between RER status and mutations in TGFbIIR (n¼14) and LOH in DCC
(n¼33) when only one of the duplicate cell lines is included for each pair of
duplicates are highly significant. The P-values are for Fisher’s exact test in 2 2
contingency tables.
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specific immune responses have been shown against MSI-induced
frameshift neopeptides (Schwitalle et al, 2008). However, under
5FU-based chemotherapy, patients with microsatellite stable
disease were found to have a significant increase in the duration
of overall survival and disease-free survival, which was not
observed for RERþ patients (Ribic et al, 2003; Carethers et al,
2004; Popat et al, 2005; Jover et al, 2006; Sargent et al, 2008).
Watanabe et al (2001) reported an improvement in 5-year
overall survival for TGFbIIR-mutant patients under 5FU-based
chemotherapy, but the results are controversial. A possible
explanation for this discrepancy with other data and with our
results lies in survival advantages gained from drugs other than
5FU used in the treatment. Our results were, of course, obtained
under 5FU monotherapy.
The proportion of cell lines in our panel with mutations in MSH6
can be expected to be too low to show any significant correlations.
This is also the case for MSH2, in which only three cell lines (LOVO,
HCT15, and DLD1) were found to carry MSH2 mutations.
The well-recognised alterations in SMAD4 and DCC in RERþ
CRCs and cell lines, as also shown in Table 2, translate into
significant differences with respect to 5FU treatment (see Figure 1).
This shows further that RER status is the major underlying
determinant of 5FU sensitivity.
Following standard doses of 5FU given by intravenous
continuous infusion, patient plasma levels reported in the
literature lie in the range of 0.06–11.3mM (188-fold) (Poorter
et al, 1995; Adjei et al, 2002), which overlaps the range of GI50
values observed in our cell line panel. This suggests that, under
standard therapy, most tumours should have responded to 5FU to
some extent, but the patients with RERþ tumours are likely to
have responded much less than those with RER  tumours. Such
patients should be identified and either given higher doses of 5FU,
or not given a drug that is very unlikely to be of benefit for them.
Our data extend significantly previously published data on 5FU
responses in cell lines. Thus, studies on a mixed panel of 14 cell
lines showed a 31-fold variation in 5FU response (Bracht et al,
2006), when compared with the 1600-fold variation found in our
study. Data from the NCI60 drug-screening programme (NSC
19893, 1806 experiments (DTP)) showed variation in GI50 values
for 5FU response between 1.6 and 107.6mM in the limited number
of CRC cell lines studied. The most extensive previous study on
5FU responses in 30 CRC lines showed a range of GI50 values
between 0.7 and 23.1mM (Mariadason et al, 2003). An analysis of
the ranked responses to 5FU in the 21 cell lines included both in
Mariadason’s et al (2003) and our study shows a significant
correlation, giving P¼0.0307 using the Wilcoxon signed-rank test.
These results suggest reasonable reproducibility in the measures
of 5FU response even when different techniques are used to
assess the response, and lend weight to the use of cell lines for
preclinical testing.
Our data agree with a much smaller study on three CRC cell
lines undertaken by Carethers et al (1999), who excluded cell cycle
alterations and differences in nucleotide uptake as a cause for their
findings. The disagreement between our results and those of
Mariadason et al (2003), who did not find RER status correlated
with 5FU response, could be explained by differences in the size of
the two cell line collections. Although the two panels contain
similar proportions of RERþ cell lines (30 and 23.5%) our panel is
more than twice the size (30 vs 77 lines with known RER status).
We did not detect a correlation between p53 mutation status and
5FU response, which agrees with Mariadason et al (2003), who
compared p53 with 5FU apoptotic response.
Although the link between mutations in KRAS and a response to
anti-EGFR-based chemotherapy in CRC is well established, the
clinical data regarding response to 5FU are more conflicting. Rosty
et al (2001) found no significant difference between KRAS mutant
and wild-type groups in the response of previously untreated CRC
patients with liver metastasis to 5FU. Other researchers report
reverse findings, with the 5FU single-agent response rate of 44% in
KRAS-mutant patients vs only 32% in wild-type patients (Etienne-
Grimaldi et al, 2008). However, the RASCAL study suggested that
mutations in KRAS have a negative effect on survival rates and
disease relapse (Russo et al, 2005). Our data do not show a
significant correlation between KRAS mutation status and 5FU
sensitivity (P¼0.2713, data not shown). Analysis of preliminary
data on TS mRNA expression and 5FU response suggests that high
TS expression may be associated with resistance to 5FU. This has
been suggested previously by others (Banerjee et al, 2002).
LS174T cells originate from trypsin treatment and LS180 cells
from scraping of the primary culture from a tumour in the same
patient (Rutzky et al, 1980). LS180 has been shown to express
E-cadherin, whereas Kinsella et al (1994) found LS174T to be
nonexpressing. This is explained by LS180 having just one
mutation in the E-cadherin gene, whereas LS174T has a second
mutation, leading to complete loss of E-cadherin expression in that
cell line (Efstathiou et al, 1999 and David Bicknell, unpublished
observations). Despite these differences, the cell lines show very
similar responses to 5FU treatment, both in the Matrigel colony-
forming assay and in SRB-measured response. This suggests that
E-cadherin expression, and hence probably epithelial mesen-
chymal transition (EMT), does not correlate with 5FU response. The
overall higher sensitivity of the four cell lines to 5FU in Matrigel
compared with our conventional assay is most likely to be because
of the difference between a colony-forming assay and a measure of
cell number in bulk culture, such as the SRB assay. However, the
data do suggest that there is no correlation between 5FU response
and the capacity of the cell lines to differentiate. This, together with
the lack of difference between LS180 and LS174T, suggests that the
cancer stem cells and differentiated cells within the cell lines do not
differ substantially in their response to 5FU.
There is now substantial evidence to support the view that cell
lines are true representatives of the tumours from which they were
derived. Thus, for example, both the frequency of specific
mutations as well as their spectrum is similar between cell lines
and tumour samples (see, e.g., Douglas et al, 2004; Sanger
Institute). In addition, the availability of duplicate cell lines that
have been separately maintained in culture for many years, and
that in nearly all cases have the same genetic changes, shows that
the genetic changes that we studied have not occurred in culture,
and hence allows for internal quality control. The use of a large,
disease-specific cell panel for drug response and related studies
has several advantages: unlimited amounts of material are
available, functional studies can be carried out, the size of the
panel represents a wide variety of types and stages of CRC, and can
help to uncover correlations that would not be observed with a
smaller number of cell lines.
We suggest that our approach of studying the response to 5FU in a
large panel of well-characterised cell lines, using a relatively high
throughput test procedure and an objective categorisation of response,
could be a model for preclinical testing of other drugs. Our results
show that our approach can be a powerful tool for the detection of
predictive markers for drug treatment responses, and that the cell line
studies are good predictors of the clinical situation.
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